Head-to-head evidence
crisaborole vs roflumilast
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: PDE4 · full Atopic Dermatitis pipeline
crisaborole · Eucrisa
Marketed by Pfizer
NCT02118792 · Phase 3 · completed
This was a randomized, quadruple-blind, vehicle-controlled trial with 763 participants. Its clinical primary efficacy endpoint—clear or almost clear skin with at least a two-grade improvement at Day 29—was met, with 31.4% success on crisaborole versus 18.0% on vehicle (p<0.001).
Next expected readout: January 2027 · NCT07162896 (registry estimate)
roflumilast · Zoryve
Marketed by Arcutis Biotherapeutics
NCT06631170 · Phase 3 · completed
The trial was randomized, fully blinded, and vehicle-controlled with a validated disease-severity measure as its primary endpoint, and roflumilast cream produced significantly more treatment successes than vehicle (31.9% vs 6.7%, P<0.0001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: August 2027 · NCT07560618 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: crisaborole's landscape · roflumilast's landscape